Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Methylephedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.54 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.54 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.53 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.53 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.50 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.50 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.50 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.96 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HBB | P68871 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylephedrine SCHEMBL7496690 | 0.98 | KDM4E (1.00) | ALDH1A1KDM4EAOC3GAAADRA2C | |
| Methylephedrine SCHEMBL338479 | 0.98 | KDM4E (1.00) | ALDH1A1KDM4EAOC3GAAADRA2C | |
| Methylephedrine SCHEMBL907677 | 0.98 | KDM4E (1.00) | ALDH1A1KDM4EAOC3GAAADRA2C | |
| Methylephedrine SCHEMBL99673 | 0.98 | KDM4E (1.00) | ALDH1A1KDM4EAOC3GAAADRA2C | |
| Methylephedrine SCHEMBL11959977 | 0.98 | KDM4E (1.00) | ALDH1A1KDM4EAOC3GAAADRA2C | |
| Methylephedrine SCHEMBL99674 | 0.98 | KDM4E (1.00) | ALDH1A1KDM4EAOC3GAAADRA2C | |
| Methylephedrine SCHEMBL338478 | 0.98 | KDM4E (1.00) | ALDH1A1KDM4EAOC3GAAADRA2C | |
| Methylephedrine SCHEMBL907777 | 0.98 | KDM4E (1.00) | ALDH1A1KDM4EAOC3GAAADRA2C | |
| Methylephedrine SCHEMBL2712293 | 0.98 | KDM4E (1.00) | ALDH1A1KDM4EAOC3GAAADRA2C | |
| Methylephedrine SCHEMBL8083321 | 0.96 | KDM4E (0.96) | ALDH1A1KDM4EAOC3GAAADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1092 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367139-A1 | COMPOUND HYDROCORTISONE AND NEOMYCIN SULFATE GRANULE AND PREPARATION METHOD THEREOF | HEBEI CHANGTIAN PHARMACEUTICAL CO LTD (CN) | 2025-12-04 | — | — | US | claimed |
| WO-2023241662-A1 | COMPOUND PARACETAMOL AND CHLORPHENAMINE MALEATE GRANULE AND PROCESS FOR PREPARING SAME | 河北长天药业有限公司 | 2023-12-21 | — | — | WO | claimed |
| CN-110934833-B | Compound paracetamol and chlorphenamine maleate granules | 河北长天药业有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114796280-A | Compound paracetamol and chlorphenamine maleate granules and preparation process thereof | 河北长天药业有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-108061777-B | Method for detecting residual quantity of 34 illegally added medicines in weight-losing health-care food | 浙江公正检验中心有限公司 | 2020-05-08 | — | — | CN | claimed |
| US-20170105934-A1 | AQUEOUS OPHTHALMIC COMPOSITION | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2017-04-20 | — | — | US | claimed |
| WO-2016001937-A2 | MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2016-01-07 | — | — | WO | claimed |
| US-20140377328-A1 | INTRAORAL SOLUBLE-TYPE FILM PREPARATION | KYUKYU PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | claimed |
| US-20120110957-A1 | METHOD FOR PREPARING RAPIDLY DISINTEGRATING FORMULATION FOR ORAL ADMINISTRATION | HANMI PHARM. CO., LTD. (KR) | 2012-05-10 | — | — | US | claimed |
| US-20100105783-A1 | Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same | HANMI PHARM. CO., LTD. (KR) | 2010-04-29 | — | — | US | claimed |
| US-20030185886-A1 | Process for the preparation of rapidly disintegrating tablet | HANMI PHARM. CO., LTD. | 2003-10-02 | — | — | US | claimed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | claimed |
| EP-1330448-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | Atherogenics, Inc. (US) | 2003-07-30 | — | — | EP | claimed |
| EP-1283703-A1 | RAPIDLY DISINTEGRATING TABLET AND PROCESS FOR THE MANUFACTURE THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2003-02-19 | — | — | EP | claimed |
| US-20020001617-A1 | Rapidly disintegrating tablet and process for the manufacture thereof | HANMI PHARM. CO., LTD. (KR) | 2002-01-03 | — | — | US | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001089485-A1 | RAPIDLY DISINTEGRATING TABLET AND PROCESS FOR THE MANUFACTURE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2001-11-29 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |